Glander, Petra <br/><br/>
Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.  [electronic resource] 

 -  Clinical transplantation  08 2018 
 - e13311 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1399-0012 
<br/><br/><label>Standard No.: </label>10.1111/ctr.13311  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Biological Availability<br/>Cost-Benefit Analysis<br/>Delayed-Action Preparations<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Glomerular Filtration Rate<br/>Graft Rejection--drug therapy<br/>Graft Survival<br/>Humans<br/>Immunosuppressive Agents--economics<br/>Kidney Failure, Chronic--economics<br/>Kidney Function Tests<br/>Kidney Transplantation--adverse effects<br/>Male<br/>Middle Aged<br/>Multicenter Studies as Topic<br/>Prognosis<br/>Prospective Studies<br/>Randomized Controlled Trials as Topic<br/>Retrospective Studies<br/>Risk Factors<br/>Tacrolimus--economics